$AMGN (Amgen Inc)

$AMGN {{ '2016-04-28T21:45:25+0000' | timeago}} • Webcast

Thousand Oaks, California-based $AMGN said in total it is expecting on the order of 80 new launches across its countries and products in 2016. Repatha is launching now in Japan, Brazil and multiple countries in Europe and the early signs are good. Kyprolis is off to a strong early start in its first markets in Europe.

$AMGN {{ '2018-01-05T14:22:45+0000' | timeago}} • Announcement

$AMGN gets US FDA's approval for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma.

$AMGN {{ '2017-12-12T13:40:51+0000' | timeago}} • Announcement

$AMGN said the final analysis of Phase 3 ASPIRE trial showed KYPROLIS combined with dexamethasone and lenalidomide  reduced the risk of death among patients with relapsed or refractory multiple myeloma by 21% and extended survival by nearly eight months, compared with patients treated with the two drugs alone.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$AMGN {{ '2017-11-14T13:04:32+0000' | timeago}} • Announcement

$AMGN announced five new subgroup analyses from the Repatha cardiovascular outcomes study (FOURIER). The study showed the addition of Repatha to statin therapy improved clinical outcomes with significant reduction of cardiovascular events in high-risk patients with peripheral artery disease and in patients with a history of heart attack.

$AMGN {{ '2017-11-06T14:31:31+0000' | timeago}} • Webcast

$AMGN said its growth brands, including Prolia, Repatha, KYPROLIS and BLINCYTO are all exhibited solid unit volume growth in 3Q17. Looking ahead to next year, the company expects to begin tackling another significant unmet medical need in migraine, as it continues to receive positive feedback on Aimovig.

$AMGN {{ '2017-10-25T22:06:17+0000' | timeago}} • Announcement

$AMGN upped its FY17 adjusted earnings forecast to $12.50 to $12.70 per share from its earlier view of $12.15 to $12.65. The company sees GAAP earnings in the range of $10.96 to $11.20 per share, with revenue ranging between $22.7Bil and $23Bil.

$AMGN {{ '2017-10-25T21:58:54+0000' | timeago}} • Announcement

$AMGN reported a flat profit of $2Bil, or $2.76 per share, for 3Q17 compared to a year ago, as the world's largest biotech drugmaker saw a 1% dip in revenue. The company, which is in the process of refreshing its product portfolio, saw its product sales dropping 1% with sales declining in some of its established products.

$AMGN {{ '2017-10-25T21:07:13+0000' | timeago}} • Infographic

$AMGN Amgen Inc Earnings AlphaGraphic: Q3 2017 Highlights

$AMGN {{ '2017-10-17T14:34:06+0000' | timeago}} • Announcement

$AMGN has entered into a neuroscience research collaboration with Boston Children's Hospital, which aims at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity.

$AMGN {{ '2017-10-05T21:56:58+0000' | timeago}} • Announcement

$AMGN said first randomized study to evaluate Imlygic (talimogene laherparepvec), an oncolytic viral therapy, in combination with a checkpoint inhibitor published in the Journal of Clinical Oncology. The study met its primary endpoint of objective response rate. Imlygic is designed to rupture cancer cells causing release of tumor-derived antigens.

$REGN {{ '2017-10-05T17:28:07+0000' | timeago}} • Announcement

Sanofi and $REGN said the U.S. Court of Appeals for the Federal Circuit has ordered new trial and vacated permanent injunction in the dispute concerning $AMGN's asserted patent claims for antibodies targeting PCSK9. This ruling means that Sanofi and $REGN will continue marketing, selling and manufacturing Praluent (alirocumab) injection in the U.S.

$AMGN {{ '2017-10-03T20:40:22+0000' | timeago}} • Announcement

$AMGN and $CTMX said they will co-develop a Probody T-cell engaging bispecific against EGFRxCD3 with CytomX leading early development. $AMGN will make an upfront payment of $40MM and purchase $20MM of $CTMX common stock.

$AMGN {{ '2017-10-03T20:38:44+0000' | timeago}} • Announcement

$AMGN and $CTMX entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX Probody T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types.

$AMGN {{ '2017-09-26T20:20:34+0000' | timeago}} • Announcement

$AMGN and Simcere Pharmaceutical Group team up to co-develop and commercialize four biosimilars in China. The collaboration includes undisclosed biosimilars in the areas of inflammation and oncology. Amgen will remain responsible for the co-development, marketing approval applications and manufacturing of the biosimilars.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$AMGN {{ '2017-09-07T20:44:44+0000' | timeago}} • Announcement

$AMGN's new data demonstrates Aimovig reducing monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet meed. Aimovig is the only investigational biologic product specifically designed to prevent migraine by blocking the CGRP receptor, which is associated with migraine activation.

$AMGN {{ '2017-09-07T12:11:23+0000' | timeago}} • Announcement

$AMGN announced results from the PATHWAY Phase 2b trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. Tezepelumab is a novel anti-thymic stromal lymphopoietin monoclonal antibody being developed by $AZN in collaboration with $AMGN.

$AMGN {{ '2017-08-29T20:44:23+0000' | timeago}} • Announcement

$AMGN announced that a new analysis showed lowering low-density lipoprotein cholesterol levels with Repatha reduced the risk of cardiovascular events in a sub-group of patients with a history of stroke from the Repatha cardiovascular outcomes study.

$AMGN {{ '2017-07-31T13:27:43+0000' | timeago}} • Announcement

$AMGN and $AGN announced the submission of a Biologics License Application (BLA) to the FDA for ABP 980, a biosimilar candidate to Herceptin (trastuzumab). These two companies are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA approval.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
SGMO (Sangamo Biosciences Inc.)
Thursday, November 9 2017 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
ARQL (ArQule Inc.)
Thursday, November 9 2017 - 2:00pm
RGEN (Repligen Corporation)
Thursday, November 9 2017 - 1:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
QGEN (Qiagen NV)
Tuesday, November 7 2017 - 2:00pm
CRIS (Curis, Inc.)
Tuesday, November 7 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, October 26 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm

AlphaGraphics you may like